Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy.

Genome Med · 2022 · PMC9367103 · PMID 35948919

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significancep > 0.05actually significant

Furthermore, we detected a numerical decrease of C>T substitutions during epirubicin treatment, but this decrease did not reach statistical significance (mean number of mutations before and after epirubicin, 22.4 versus 16.5; p > 0.05; Additional file 3 : Fig.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.